MedTrace Logo

Study of SON-1010 (IL12-FHAB) in Healthy Adults

NCT05408572 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2023-09-06

No results posted yet for this study

Summary

SB102 is a randomized, double-blind, single center, placebo-controlled study in healthy adults starting with sentinel participants at each dose level to carefully assess the safety, tolerability, PK, and PD of SON-1010.

Conditions

  • Healthy Adult

Interventions

BIOLOGICAL

SON-1010 (IL12-FHAB)

SON-1010 is a single-chain human IL-12 cytokine linked to a single-chain variable region known as the FHAB.

Sponsors & Collaborators

  • Sonnet BioTherapeutics

    lead INDUSTRY

Principal Investigators

  • Richard Kenney, MD · Sonnet BioTherapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
54 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-27
Primary Completion
2023-02-28
Completion
2023-05-17

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05408572 on ClinicalTrials.gov